7 results on '"Jeffrey Finkelstein"'
Search Results
2. Hybrid W-Band/Baseband Transmission for Fixed-Mobile Convergence Supported by Heterodyne Detection with Data-Carrying Local Oscillator.
- Author
-
Shuyi Shen, Qi Zhou 0007, You-Wei Chen, Shuang Yao, Rui Zhang 0048, Yahya Alfadhli, Shang-Jen Su, Jeffrey Finkelstein, and Gee-Kung Chang
- Published
- 2020
3. Spectrum-efficient 50-Gbps Long-Range Optical Access over 85-km SSMF via DML Using Windowed OFDM Supporting Quasi-Gapless Asynchronous Multiband Transmission.
- Author
-
Shuyi Shen, Thavamaran Kanesan, Peng-Chun Peng, Feng Lu 0007, Mu Xu, Siming Liu, Chin-Wei Hsu, Qi Zhou 0007, Yahya M. Alfadhli, Hyung Joon Cho, Sufian Mousa Mitani, Jeffrey Finkelstein, and Gee-Kung Chang
- Published
- 2018
4. Polynomial-time kernel reductions.
- Author
-
Jeffrey Finkelstein and Benjamin Hescott
- Published
- 2016
5. Assessment of Postural Discomfort
- Author
-
Larry D. Haugh, Jeffrey Finkelstein, Rosemary Bonney, and Gerald Weisman
- Subjects
medicine.medical_specialty ,Physical medicine and rehabilitation ,Visual analogue scale ,05 social sciences ,medicine ,0501 psychology and cognitive sciences ,General Medicine ,Visual feedback ,Psychology ,050107 human factors ,050105 experimental psychology ,Lateral bending - Abstract
Tasks requiring awkward postures are common in industry and no guidelines have been developed for “good,” or safe, postures. The present study compares nine different postures in terms of subjective assessments of discomfort. Subjects (five men and five women) maintained each of the postures for ten minutes, and provided discomfort ratings on a visual analog scale. An electrogoniometer and a computerized visual feedback system enabled subjects to adopt and maintain the required postures easily. Results show that the discomfort ratings do discriminate among different postures. Postures that included lateral bending were rated as more uncomfortable than postures involving flexion and/or rotation. The findings confirm the hypothesis that some postures cause greater discomfort than others and provide a basis for developing a posture analysis system. Such a system might eventually be used to specify guidelines for posture safety limits in the industrial workplace.
- Published
- 1990
6. Abstract 4701: NY-ESO T cells administered post ASCT for MM exhibit extended functionality without exhaustion in a natural pattern of effector and memory programming
- Author
-
Ashraf Badros, Alan D. Bennett, Eduardo Davila, Tom Holdich, Sandra Wesphal, Nancy M. Hardy, Marylène Fortin, Bent K. Jakobsen, Aaron P. Rapoport, Nick Pumphrey, Brendan M. Weiss, Helen K. Tayton-Martin, Carl H. June, Gwendolyn Binder-Scholl, Ryan Wong, Jeffrey Finkelstein, Bruce L. Levine, Naseem Kerr, Edward A. Stadtmauer, Sunita Philip, Sarah Bond, Andrew B. Gerry, Michael Kalos, Yoav Peretz, Saul Yanovich, Luca Melchiori, Lilliam Ribeiro, Joanna E. Brewer, Dan T. Vogl, Simon F. Lacey, and Jean A. Yared
- Subjects
Cancer Research ,business.industry ,CD28 ,medicine.disease ,Tumor antigen ,Granzyme B ,Cytokine release syndrome ,Immune system ,Oncology ,Antigen ,Immunology ,Medicine ,Cytotoxic T cell ,business ,Multiple myeloma - Abstract
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Adoptive immunotherapy for cancer has been limited by a lack of antigen specificity, low levels of target expression, and failure to break self-tolerance. We hypothesized that infusion of genetically modified tumor-specific T cells following autologous stem cell transplant (ASCT) may overcome these barriers for multiple myeloma (MM). To test this, we conducted a phase I/II clinical trial ([NCT01352286][1]) in which T cells engineered with an HLA-A*0201 restricted, affinity-enhanced TCR recognizing NY-ESO-1 / LAGE-1 peptides (NY-ESOc259-T), were infused in the setting of profound lymphodepletion that accompanies high-dose chemotherapy given with ASCT. HLA-A*0201 MM patients eligible for ASCT, with antigen positive tumor were enrolled. NY-ESOc259-T was manufactured in a 10 day process using anti-CD3/CD28 microbeads and lentiviral vector, and was administered two days following ASCT. IMWG criteria were used to assess response at day 100 with the addition of a near complete response category (nCR) due to the common occurrence of oligoclonal banding observed following rapid post-ASCT immune reconstitution. Blood and marrow samples were taken at multiple timepoints for serum cytokine analysis, NY-ESOc259-T persistence and trafficking, multiparameter flow analysis to examine the phenotype and function of NY-ESOc259-T, and tumor biomarker analysis. 25 of 29 enrolled patients were infused. A mean of 2.8 × 109 engineered cells were administered (range 8.3 × 108-4.2 × 109), and the average transduction efficiency was 33% (range 30%-45%). Patients tended to have advanced disease (64% chromosomal abnormalities, and 24% prior ASCT). At 3 months, 67% (16/24) and 58% (14/24) of patients were in VGPR and nCR or better, respectively. Infusions were well-tolerated and no cytokine release syndrome was reported. NY-ESOc259-T persisted at 6 months in all but one patient, and in a subset of patients at 2 years; marrow infiltration was consistently observed from day 7 through day 180. NY-ESOc259-T initially displayed a dominant activated effector phenotype which converted towards a dominant effector memory phenotype by 1 year post infusion, in a pattern that mirrored clinical responses. Persisting cells demonstrated a polyfunctional response (IFN-γ and TNF-α) with a cytotoxic (CD107a and granzyme B) signature without overexpression of exhaustion markers (PD-1, LAG-3, and TIM-3). Tumor biomarker analysis is ongoing. MM relapse occurred in 13/25 patients. This data show that NY-ESOc259-T cells exhibit robust trafficking and expansion, durable persistence without exhaustion, and follow a natural immune expansion and contraction pattern consistent with an antigen-driven mechanism of action. Relapse correlated with a loss of persistence or tumor antigen escape, suggesting that targeting multiple antigens and maintenance infusions may increase durable remissions. Citation Format: Aaron Rapoport, Edward Stadtmauer, Luca Melchiori, Ryan Wong, Eduardo Davila, Gwendolyn Binder-Scholl, Tom Holdich, Dan Vogl, Brendan Weiss, Jeffrey Finkelstein, Simon Lacey, Sarah Bond, Marylene Fortin, Yoav Peretz, Joanna Brewer, Alan Bennett, Andrew Gerry, Nick Pumphrey, Helen Tayton-Martin, Lilliam Ribeiro, Ashraf Badros, Saul Yanovich, Nancy Hardy, Jean Yared, Naseem Kerr, Sunita Philip, Sandra Wesphal, Bruce L. Levine, Carl June, Michael Kalos, Bent Jakobsen. NY-ESO T cells administered post ASCT for MM exhibit extended functionality without exhaustion in a natural pattern of effector and memory programming. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4701. doi:10.1158/1538-7445.AM2015-4701 [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01352286&atom=%2Fcanres%2F75%2F15_Supplement%2F4701.atom
- Published
- 2015
7. Abstract 4575: Correlates of clinical response following autologous stem cell transplant and adoptive immunotherapy with engineered T cells expressing an affinity-enhanced T cell receptor in patients with mutliple myeloma
- Author
-
Sunita Philip, Karen Dengel, Minnal Gupta, Alan D. Bennett, Tatiana Mikheeva, Carl H. June, Helen K. Tayton-Martin, Edward A. Stadtmauer, Bent K. Jakobsen, Jeffrey Finkelstein, Andrew B. Gerry, Ashraf Z. Bados, Lilliam Ribeiro, Joanna E. Brewer, Dan T. Vogl, Elizabeth Veloso, Bruce L. Levine, Saul Yanovich, Zhaohui Zheng, Gorgun Akpek, Kelly-Marie Betts, Irina Kulikovskaya, Gwendolyn Binder-Scholl, Erica Suppa, Naseem Kerr, Michael Kalos, Sandra Westphal, Aaron P. Rapoport, Brendan M. Weiss, Dominic P. Smethurst, and Nick Pumphrey
- Subjects
Cancer Research ,Chemotherapy ,biology ,business.industry ,T cell ,medicine.medical_treatment ,medicine.disease ,medicine.anatomical_structure ,Oncology ,Antigen ,Immunology ,biology.protein ,Medicine ,Cancer/testis antigens ,IL-2 receptor ,Antibody ,Stem cell ,business ,Multiple myeloma - Abstract
Background: Adoptive immunotherapy for cancer has been limited by lack of antigen specificity, low levels of target expression, and failure to break self-tolerance. We are conducting an early phase clinical trial (NCT01352286) attempting to overcome these barriers using T cells engineered with an HLA-A0201 restricted, affinity-enhanced TCR that recognizes an epitope expressed by the NY-ESO-1 and LAGE-1 cancer testis antigens; these cells are infused in the setting of profound lymphodepletion that accompanies high-dose chemotherapy with autologous stem cell transplant (aSCT) for patients with high risk or relapsed multiple myeloma (MM). Methods: Inclusion criteria include: 1) eligibility for aSCT, 2) PS of 0-2, 3) high risk MM or relapse after prior therapy, 4) HLA-A0201 positive, and 5) NY-ESO-1 and/or LAGE-1 positive tumor by PCR. CD25 depleted T cells are activated and expanded using anti-CD3/28 antibody conjugated microbeads, and genetically modified with a lentiviral vector. T cells are administered four days after high dose melphalan and two days following auto-SCT. Patients are evaluated for MM responses in accordance with the IMWG criteria at 6 weeks, and 3 and 6 months. At 3 months, patients with adequate marrow function start lenalidomide maintenance. Blood and marrow are monitored for persistence of engineered cells by qPCR and by surface expression of the NY-ESO-1 / LAGE-1 TCR using dextramerTM reagents. NY-ESO-1 and LAGE-1 antigen expression in marrow was assessed by qRT-PCR at baseline and post infusion. Results: As of November 2012, 21 patients have been enrolled, 15 have been infused; 4 were taken off study prior to infusion due to disease progression. An average of 2.7 x 109 engineered T cells were administered per patient (range 8.3 x 108-4.2 x 109), and the average transduction efficiency was 33% (range 30%-45%). More than 50% (8/15) of patients have high risk chromosomal abnormalities, and 3 (20%) have received prior aSCT. At 3 months post aSCT, 73% of patients were in a very good partial response (VGPR) or better. Gastrointestinal toxicity resulting from autologous GVHD (aGVHD) occurred in a subset of patients at a higher rate than reported following aSCT alone or aSCT and T cell infusion, and was resolved in all cases. Infused T cells typically showed peak expansion in blood at day 14, followed by durable persistence in blood and marrow at 6-12 months in all but one patient. Disease progression is typically accompanied by very low levels or loss of engineered T cell persistence or loss of target antigen on tumor. Conclusions: We report for the first time that possible correlates of clinical response in this study include persistence of engineered T cells and loss of antigen, suggesting specific activity of the infused cells. Infusions are well tolerated with a possible risk of manageable aGVHD. Citation Format: Aaron P. Rapoport, Edward A. Stadtmauer, Dan T. Vogl, Brendan Weiss, Gwendolyn K. Binder-Scholl, Dominic P. Smethurst, Jeffrey Finkelstein, Irina Kulikovskaya, Minnal Gupta, Erica Suppa, Tatiana Mikheeva, Joanna E. Brewer, Alan D. Bennett, Andrew B. Gerry, Nick J. Pumphrey, Helen K. Tayton-Martin, Lilliam Ribeiro, Elizabeth Veloso, Zhaohui Zheng, Ashraf Z. Bados, Saul Yanovich, Gorgun Akpek, Karen Dengel, Naseem Kerr, Sunita Philip, Kelly-Marie Betts, Sandra Westphal, Bruce L. Levine, Bent K. Jakobsen, Carl H. June, Michael Kalos. Correlates of clinical response following autologous stem cell transplant and adoptive immunotherapy with engineered T cells expressing an affinity-enhanced T cell receptor in patients with mutliple myeloma. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4575. doi:10.1158/1538-7445.AM2013-4575
- Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.